U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07038369) titled 'A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations' on June 18.
Brief Summary: This is a Phase 1, open-label study to evaluate the safety and tolerability of ATV-1601 administered orally in adults with AKT1 E17K-mutant, advanced solid tumors and also in HR+/HER2- advanced and metastatic breast cancer, with or without fulvestrant.
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Breast Cancer
Breast Carcinoma
Breast Neoplasms
ER Positive Breast Cancer
Cervical Cancers
Cervical Neoplasms
Cervical Carcinoma
Triple Negative Breast Cancer
Gynecologic Canc...